Comprehensive clinical evaluation of ceftazidime and avibactam sodium versus polymyxin in the treatment of drug-resistant Gram-negative bacterial infections
Objective To compare the comprehensive clinical value of ceftazidime and avibactam sodium(CAZ-AVI)and polymyxin in the treatment of drug-resistant Gram-negative bacterial infections,and to provide a reference for the rational use of drugs in the clinic.Methods A systematic literature review was conducted to evaluate ehe effectiveness,safety,economy,innovativeness,appropriateness and accessibility of CAZ-AVI and polymyxin.Results In terms of effectiveness,the clinical cure rate and microbial clearance rate were higher in the CAZ-AVI group than in the polymyxin group.In terms of safety,the CAZ-AVI group had significantly lower mortality and incidence of renal injury compared to the polymyxin group.In terms of innovativeness,CAZ-AVI was superior to polymyxin.In terms of appropriateness,both were available in injectable form,though polymyxin offers a wider variety of formulations.Accessibility was comparable between the two.In terms of economy,polymyxin B was superior to ceftazidime avibactam sodium.Conclusion CAZ-AVI demonstrates higher effectiveness,safety,and innovativeness,indicating a higher clinical comprehensive value compared to polymyxin.
NETL
NSTL
万方数据
